AdooQ BioScience is a supplier of biochemicals located in Irvine, CA since 2006. In the past five years, we have been a renowned name engaged in manufacturing and supplying small molecule inhibitors including kinase inhibitors on kinds of signal pathway, such as PI3K, AKT, HDAC, MARP etc.
Company WebsitePP121 is a dual inhibitor of receptor tyrosine kinases (RTKs) (IC50 < 0.02 ??M for Abl, Src, VEGFR-2 and PDGFR) and PI 3-K family kinases (IC50 < 0.06 ??M for p110??, DNA-PK and mTOR).
More Information Supplier PagePP121 is a dual inhibitor of receptor tyrosine kinases (RTKs) (IC50 < 0.02 ??M for Abl, Src, VEGFR-2 and PDGFR) and PI 3-K family kinases (IC50 < 0.06 ??M for p110??, DNA-PK and mTOR).
More Information Supplier PagePP121 is a dual inhibitor of receptor tyrosine kinases (RTKs) (IC50 < 0.02 ??M for Abl, Src, VEGFR-2 and PDGFR) and PI 3-K family kinases (IC50 < 0.06 ??M for p110??, DNA-PK and mTOR).
More Information Supplier PagePP2 is a selective inhibitor of Src-family tyrosine kinases. Inhibits p56lck and p59fynT (IC50 values are 4 and 5 nM respectively). Displays > 10000-fold selectivity over ZAP-70 and JAK2. Moderately inhibits CSK (IC50 = 0.73 ??M).
More Information Supplier PagePP2 is a selective inhibitor of Src-family tyrosine kinases. Inhibits p56lck and p59fynT (IC50 values are 4 and 5 nM respectively). Displays > 10000-fold selectivity over ZAP-70 and JAK2. Moderately inhibits CSK (IC50 = 0.73 ??M).
More Information Supplier PagePP2 is a selective inhibitor of Src-family tyrosine kinases. Inhibits p56lck and p59fynT (IC50 values are 4 and 5 nM respectively). Displays > 10000-fold selectivity over ZAP-70 and JAK2. Moderately inhibits CSK (IC50 = 0.73 ??M).
More Information Supplier PagePP2 is a selective inhibitor of Src-family tyrosine kinases. Inhibits p56lck and p59fynT (IC50 values are 4 and 5 nM respectively). Displays > 10000-fold selectivity over ZAP-70 and JAK2. Moderately inhibits CSK (IC50 = 0.73 ??M).
More Information Supplier PagePP2 is a selective inhibitor of Src-family tyrosine kinases. Inhibits p56lck and p59fynT (IC50 values are 4 and 5 nM respectively). Displays > 10000-fold selectivity over ZAP-70 and JAK2. Moderately inhibits CSK (IC50 = 0.73 ??M).
More Information Supplier PagePP242 is a potent and selective mTOR inhibitor in both mTORC1 and mTORC2.
More Information Supplier PagePP242 is a potent and selective mTOR inhibitor in both mTORC1 and mTORC2.
More Information Supplier PagePP242 is a potent and selective mTOR inhibitor in both mTORC1 and mTORC2.
More Information Supplier PagePP242 is a potent and selective mTOR inhibitor in both mTORC1 and mTORC2.
More Information Supplier PagePP242 is a potent and selective mTOR inhibitor in both mTORC1 and mTORC2.
More Information Supplier PagePPQ-102 is a compound that targets intracellular nucleotide binding domain(s) of CFTR and inhibits CFTR- mediated chloride current in a voltage-dependent and reversible manner.
More Information Supplier PagePPQ-102 is a compound that targets intracellular nucleotide binding domain(s) of CFTR and inhibits CFTR- mediated chloride current in a voltage-dependent and reversible manner.
More Information Supplier PagePPQ-102 is a compound that targets intracellular nucleotide binding domain(s) of CFTR and inhibits CFTR- mediated chloride current in a voltage-dependent and reversible manner.
More Information Supplier PagePQ 401 is a cell-permeable phenylquinolinyl-urea compound that inhibits IGF-1R autophosphorylation.
More Information Supplier PagePQ 401 is a cell-permeable phenylquinolinyl-urea compound that inhibits IGF-1R autophosphorylation.
More Information Supplier PagePQ 401 is a cell-permeable phenylquinolinyl-urea compound that inhibits IGF-1R autophosphorylation.
More Information Supplier PagePQ 401 is a cell-permeable phenylquinolinyl-urea compound that inhibits IGF-1R autophosphorylation.
More Information Supplier PagePQ 401 is a cell-permeable phenylquinolinyl-urea compound that inhibits IGF-1R autophosphorylation.
More Information Supplier PagePR-104 is a non-toxic, small-molecule, hypoxia-activated, 3,5-dinitrobenzamide nitrogen mustard pre-prodrug with potential antitumor activity.
More Information Supplier PagePR-104 is a non-toxic, small-molecule, hypoxia-activated, 3,5-dinitrobenzamide nitrogen mustard pre-prodrug with potential antitumor activity.
More Information Supplier PagePR-104 is a non-toxic, small-molecule, hypoxia-activated, 3,5-dinitrobenzamide nitrogen mustard pre-prodrug with potential antitumor activity.
More Information Supplier PagePR-171 (Carfilzomib) is a tetrapeptide epoxyketone and a selective proteasome inhibitor. It is an analog of epoxomicin.
More Information Supplier PagePR-171 (Carfilzomib) is a tetrapeptide epoxyketone and a selective proteasome inhibitor. It is an analog of epoxomicin.
More Information Supplier PagePR-171 (Carfilzomib) is a tetrapeptide epoxyketone and a selective proteasome inhibitor. It is an analog of epoxomicin.
More Information Supplier PagePR-171 (Carfilzomib) is a tetrapeptide epoxyketone and a selective proteasome inhibitor. It is an analog of epoxomicin.
More Information Supplier PagePR-171 (Carfilzomib) is a tetrapeptide epoxyketone and a selective proteasome inhibitor. It is an analog of epoxomicin.
More Information Supplier PagePR-619 is a cell-permeable, reversible, and broad-spectrum inhibitor of the deubiquitinylating enzymes (DUBs).
More Information Supplier PagePR-619 is a cell-permeable, reversible, and broad-spectrum inhibitor of the deubiquitinylating enzymes (DUBs).
More Information Supplier PagePR-619 is a cell-permeable, reversible, and broad-spectrum inhibitor of the deubiquitinylating enzymes (DUBs).
More Information Supplier PagePR-619 is a cell-permeable, reversible, and broad-spectrum inhibitor of the deubiquitinylating enzymes (DUBs).
More Information Supplier PagePR-619 is a cell-permeable, reversible, and broad-spectrum inhibitor of the deubiquitinylating enzymes (DUBs).
More Information Supplier PagePralatrexate is an antifolate (a folate analogue metabolic inhibitor) designed to accumulate preferentially in cancer cells.
More Information Supplier PagePralatrexate is an antifolate (a folate analogue metabolic inhibitor) designed to accumulate preferentially in cancer cells.
More Information Supplier PagePralatrexate is an antifolate (a folate analogue metabolic inhibitor) designed to accumulate preferentially in cancer cells.
More Information Supplier PagePralatrexate is an antifolate (a folate analogue metabolic inhibitor) designed to accumulate preferentially in cancer cells.
More Information Supplier PagePramipexole is a dopamine agonist of the non-ergoline class indicated for treating early-stage Parkinson’s disease (PD) and restless legs syndrome (RLS).
More Information Supplier PagePramipexole dihydrochloride is a dopamine receptor agonist exhibiting selectivity for the D3 receptor.
More Information Supplier PagePramipexole dihydrochloride is a dopamine receptor agonist exhibiting selectivity for the D3 receptor.
More Information Supplier PagePramipexole dihydrochloride is a dopamine receptor agonist exhibiting selectivity for the D3 receptor.
More Information Supplier PagePramipexole is a dopamine agonist of the non-ergoline class indicated for treating early-stage Parkinson’s disease (PD) and restless legs syndrome (RLS).
More Information Supplier PagePramipexole is a dopamine agonist of the non-ergoline class indicated for treating early-stage Parkinson’s disease (PD) and restless legs syndrome (RLS).
More Information Supplier PagePramipexole is a dopamine agonist of the non-ergoline class indicated for treating early-stage Parkinson’s disease (PD) and restless legs syndrome (RLS).
More Information Supplier PagePramipexole is a dopamine agonist of the non-ergoline class indicated for treating early-stage Parkinson’s disease (PD) and restless legs syndrome (RLS).
More Information Supplier Page
